Advertisement

Gewinnung und Präparation von peripheren Blutstammzellen

  • M. Wiesneth

Zusammenfassung

Die Möglichkeit, periphere Blutstammzellen durch Wachstumsfaktoren zu mobilisieren und in großer Menge durch Zytaphereseverfahren zu gewinnen, hat neue Perspektiven sowohl für die autologe als auch für die allogene Transplantation hämatopoetischer Vorläuferzellen eröffnet. Blutstammzellen sind im Vergleich zum Knochenmark einfacher und risikoärmer zu gewinnen, bieten eine höhere Vorläuferzellzahl, führen zu einer rascheren hämatologischen und immunologischen Rekonstitution nach Transplantation und erleichtern neue Behandlungsstrategien mit In-vitro-Manipulation des Transplantates bis hin zur zellulären Immuntherapie und Gentherapie.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Adkins DR (1998) Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor (letter). J Clin Oncol 16: 812–813PubMedGoogle Scholar
  2. 2.
    Anderlini P, Przepiorka D, Lauppe J et al. (1997) Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 97: 485–487PubMedCrossRefGoogle Scholar
  3. 3.
    Anderlini P, Przepiorka D, Seong D et al. (1996) Clinical toxicity and laboratory effects of granulocyte colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors and analysis of charges for the procedures. Transfusion 36: 590–595PubMedCrossRefGoogle Scholar
  4. 4.
    Anderlini P, Przepiorka D, Seong D et al. (1996) Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 94: 155–158PubMedCrossRefGoogle Scholar
  5. 5.
    Bahçeci E, Read EJ, Leitman S et al. (2000) CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Brit J Haematol 108: 408–414CrossRefGoogle Scholar
  6. 6.
    Banchereau J, Briere F, Caux, C et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767–811PubMedCrossRefGoogle Scholar
  7. 7.
    Becker PS, Wagle M, Matous S et al. (1997) Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 3: 45–49PubMedGoogle Scholar
  8. 8.
    Bender JG, Lum L, Unverzagt KL et al. (1994) Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bone Marrow Transplant 13: 479–485PubMedGoogle Scholar
  9. 9.
    Bender JG, To LB, Williams SF, Schwartzberg L (1992) Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1: 329–341PubMedCrossRefGoogle Scholar
  10. 10.
    Bensinger WI, Appelbaum F, Rowley S et al. (1995) Factors that influence collection and engraftment of autologous peripheral- blood stem cells. J Clin Oncol 13: 2547–2555PubMedGoogle Scholar
  11. 11.
    Bensinger WI, Longin K, Appelbaum F et al. (1994) Peripheral blood stem cells collected after recombinant garnulocyte stimulating factor: an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87: 825–831PubMedCrossRefGoogle Scholar
  12. 12.
    Bensinger WI, Storb R (2001) Allogeneic peripheral blood stem cell transplantation. Rev Clin Exp Hematol 5: 67–86PubMedCrossRefGoogle Scholar
  13. 13.
    Bensinger WI, Weaver CH, Appelbaum FR et al. (1995) Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85: 1655–1658PubMedGoogle Scholar
  14. 14.
    Berenson RJ, Andrews RG, Bensinger WI et al. (1988) Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 81: 951–955PubMedCrossRefGoogle Scholar
  15. 15.
    Bond VP, Cronkite EP, Fliedner TM et al. (1958) Deoxyribonucleic acid synthesizing cells in peripheral blood of normal human beings. Science 128: 202–203PubMedCrossRefGoogle Scholar
  16. 16.
    Bosse R, Kulmburg P, von Kalle C et al. (2000) Production of stemcell transplants according to good manufacturing practice. Ann Hematol 79: 469–476PubMedCrossRefGoogle Scholar
  17. 17.
    Broxmeyer HE, Lu L, Cooper S et al. (1995) Flt3 ligand stimulates/ costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 23: 1121–1129PubMedGoogle Scholar
  18. 18.
    Brugger W, Bross KJ, Glatt M et al. (1994) Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83: 636–640PubMedGoogle Scholar
  19. 19.
    Calvo W, Fliedner TM, Herbst E et al. (1967) Regeneration of blood- forming organs after autologous leukocyte transfusion in lethally irradiated dogs. II. Distribution and cellularity of the marrow in irradiated and transfused animals. Blood 47 (Suppl 4): 593–601Google Scholar
  20. 20.
    Cavins JS, Scheer SC, Thomas ED, Ferrebee JW (1964) The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at -80°C. Blood 23: 38–43PubMedGoogle Scholar
  21. 21.
    Cebon J, Layton JE, Maher D, Morstyn G (1994) Endogenous haematopoietic growth factors in neutropenia and infection. Br J Haematol 86: 265–274PubMedCrossRefGoogle Scholar
  22. 22.
    Cesaro S, Marson P, Gazzola MV et al. (2002) The use of cytokine- stimulated healthy donors in allogeneic stem cell transplantation. Haematologica 87 (Suppl 1): 35–41PubMedGoogle Scholar
  23. 23.
    Champlin R, Schmitz N, Horowitz M et al. (2000) Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95: 3702–3709PubMedGoogle Scholar
  24. 24.
    Clark RE, Brammer CG (1998) Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transplant 22: 859–863PubMedCrossRefGoogle Scholar
  25. 25.
    Copelan EA, Ceselski SK, Ezzone SA et al. (1997) Mobilization of peripheral blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, Non-Hodgkin’s lymphoma and Hodgkin’s disease. J Clin Oncol 15: 759–765PubMedGoogle Scholar
  26. 26.
    Demirer T, Buckner CD, Golley T et al. (1996) Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 17: 937–941PubMedGoogle Scholar
  27. 27.
    Demirer T, Buckner CD, Storer B et al. (1997) Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 15: 684–690PubMedGoogle Scholar
  28. 28.
    Demirkazik A, Kessinger A, Armitage JO et al. (2001) Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation. Bone Marrow Transplant 28: 207–212PubMedCrossRefGoogle Scholar
  29. 29.
    Dercksen MW, Rodenhuis S, Dirkson MKA et al. (1995) Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral- blood stem-cell transplantation. J Clin Oncol 13: 1922–1932PubMedGoogle Scholar
  30. 30.
    Desikan KR, Tricot G, Munshi NC et al. (2001) Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 112: 242–247PubMedCrossRefGoogle Scholar
  31. 31.
    Drake M, Ranaghan L, Morris TC et al. (1997) Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 98: 745–749PubMedCrossRefGoogle Scholar
  32. 32.
    Dreger P, Haferlach T, Eckstein V et al. (1994) G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 87: 609–613PubMedCrossRefGoogle Scholar
  33. 33.
    Dreger P, Kloss M, Petersen B et al. (1995) Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 86: 3970–3978PubMedGoogle Scholar
  34. 34.
    Dreger P, Suttorp M, Haferlach T et al. (1993) Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 81: 1404–1407PubMedGoogle Scholar
  35. 35.
    Duarte RF, Franf DA (2002) The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance. Leuk Lymphoma 43: 1179–1187PubMedCrossRefGoogle Scholar
  36. 36.
    Dührsen U, Villeval JL, Boyd J et al. (1988) Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72: 2074–2081PubMedGoogle Scholar
  37. 37.
    Elias AD, Ayash L, Anderson KC et al. (1992) Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 79: 3036–3044PubMedGoogle Scholar
  38. 38.
    Engelhardt M, Bertz H, Waller CF et al. (1999) High- versus standard-dose filgrastim (rhG-CSF) from mobilization of peripheralblood progenitor cells from allogeneic donors and CD34+ immunoselection. J Clin Oncol 17: 2160–2171PubMedGoogle Scholar
  39. 39.
    Facon T, Harousseau J-L, Maloisel F et al. (1999) Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 94: 1218–1225PubMedGoogle Scholar
  40. 40.
    Falzetti F, Aversa F, Minelli Ö, Tabilio A (1999) Spontaneous rupture of spleen during peripheral blood stem-cell mobilization in a healthy donor. Lancet 353: 555PubMedCrossRefGoogle Scholar
  41. 41.
    Fischer J, Unkrig C, Ackermann M et al. (1994) Intra-day CD34+ cell counts depend on time to application and correlate with the resulting G-CSF plasma level after steady-state mobilization of PBPC (abstract). Blood 84 (Suppl 1): 82Google Scholar
  42. 42.
    Fliedner TM, Körbling M, Arnold R et al. (1979) Collection and cryopreservation of mononuclear blood leukocytes and of CFU- C in man. Exp Hematol 7 (Suppl): 398–408PubMedGoogle Scholar
  43. 43.
    Fritsch G, Scharner D, Fröschl G et al. (2000) Selection of CD34- positive blood cells for allogeneic transplantation: Approaches to optimize CD34-cell recovery, purity, viability, and T-cell depletion. Onkologie 23: 449–456PubMedCrossRefGoogle Scholar
  44. 44.
    Fruehauf S, Haas R, Conradt C et al. (1995) Peripheral blood progenitor cell (PBPC) counts during steady state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 85: 2619–2626PubMedGoogle Scholar
  45. 45.
    Funke I, Eil A, Krug E, Maccari B et al. (1999) Collection of allogeneic and autologous blood stem cells: reasons for poor mobilization (abstract). Infusionsther Transfusionsmed 26 (Suppl 1): 55Google Scholar
  46. 46.
    Funke I, Nowak S, Eil A. et al. (1999) Long-term follow-up of allogeneic blood stem cell donors mobilized with G-CSF (abstract). Infusionsther Transfusionsmed 26 (Suppl 1): 52Google Scholar
  47. 47.
    Gee A (1995) Purging of peripheral blood stem cell grafts. Stem Cells 13 (Suppl 3): 52–62PubMedCrossRefGoogle Scholar
  48. 48.
    Geissler K, Peschel C, Niederwieser D et al. (1995) Effect of interleukin-3 pretreatment on granulocyte-macrophage colony-stimulating factor induced mobilization of circulating hematopoietic progenitor cells. Br J Haematol 91: 299–305PubMedCrossRefGoogle Scholar
  49. 49.
    Gianni AM, Siena S, Bregni M et al. (1989) Granulocyte-macrophage colony-stimulating factor to harvest circulating haemo- poietic stem cells for autotransplantation. Lancet 2: 580–584PubMedCrossRefGoogle Scholar
  50. 50.
    Glaspy JA (1999) Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 23 (Suppl 2): S21-S27PubMedCrossRefGoogle Scholar
  51. 51.
    Gluckman E (2001) Hematopoietic stem-cell transplants using umbilical-cord blood. N Engl J Med 344: 1815–1822CrossRefGoogle Scholar
  52. 52.
    Goldberg SL, Mangan KF, Klumpp TR et al. (1995) Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. J Hematother 4: 85–90PubMedCrossRefGoogle Scholar
  53. 53.
    Goldman J. (1995) Peripheral blood stem cells for allografting. Blood 85: 1413–1415PubMedGoogle Scholar
  54. 54.
    Goodman JW, Hodgson GS (1962) Evidence for stem cells in the peripheral blood of mice. Blood 19: 702–714PubMedGoogle Scholar
  55. 55.
    Grigg AP, Roberts AW, Raunow H et al. (1995) Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 86: 4437–4445PubMedGoogle Scholar
  56. 56.
    Gutensohn K, Serke S, Cassens U et al. (1996) Durchflusszytometrische Analyse CD34-exprimierender hämatopoetischer Zellen in Blut und Zytaphereseprodukten. Infusionsther Tranfusionsmed 23 (Suppl 2): 1–23Google Scholar
  57. 57.
    Haas R, Ehrhardt R, Witt B et al. (1993) Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following highdose chemotherapy in non-Hodgkin’s lymphoma. Bone Marrow Transplant 12: 643–649PubMedGoogle Scholar
  58. 58.
    Haas R, Ho AD, Bredthauer U et al. (1990) Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 18: 94–98PubMedGoogle Scholar
  59. 59.
    Haas R, Möhle R, Fruehauf S et al. (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83: 3787–3794PubMedGoogle Scholar
  60. 60.
    Haas R, Witt B, Möhle R et al. (1995) Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 85: 3754–3761PubMedGoogle Scholar
  61. 61.
    Handgretinger R, Klingebiel T, Lang P et al. (2001) Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27: 777–783PubMedCrossRefGoogle Scholar
  62. 62.
    Handgretinger R, Schumm M, Lang P et al. (1999) Transplantation of megadoses of purified haploidentical stem cells. Ann N YAcad Sci 872: 351–362CrossRefGoogle Scholar
  63. 63.
    Hasenclever D, Sextro M (1996) Safety of AlloPBPCT donors: biometrical considerations on monitoring long-term risks. Bone Marrow Transplant 17 (Suppl 2): 28–30Google Scholar
  64. 64.
    Heil G, Hoelzer D, Sanz MA et al. (2002) Long-term survival from a phase 3 study of Filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia (abstract). Blood 100: 5Google Scholar
  65. 65.
    Hepburn MD, Nagesh K, Heppleston AD (2001) Timing of the appearance of multipotential and committed haemopoietic progenitors in peripheral blood after mobilization in patients with lymphoma. Clin Lab Haematol 23: 119–124PubMedCrossRefGoogle Scholar
  66. 66.
    Hitzler WE, Wolf S, Runkel S, Kunz-Kostomanolakis M (2001) Comparison of intermittent- and continuous-flow cell separators for the collection of autologous peripheral blood progenitor cells in patients with hematologic malignancies. Transfusion 41: 1562–1566PubMedCrossRefGoogle Scholar
  67. 67.
    Höglund M, Smedmyr B, Simonsson B et al. (1996) Dose-dependent mobilization of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHu-CSF. Bone Marrow Transplant 18: 19–27PubMedGoogle Scholar
  68. 68.
    Holowiecki J, Wojciechowska M, Giebel S et al. (2000) Ifosfamide, etoposide, epirubicine and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients. Transplantation Proceedings 32: 1412–1415PubMedCrossRefGoogle Scholar
  69. 69.
    Huber HM, Heiden M, Seitz R (1999) Hämatopoetische Stammzellen. Zulassung und Qualitätskontrollen. Bundesgesundheitsbl- Gesundheitsforsch-Gesundheitsschutz 42: 105–112CrossRefGoogle Scholar
  70. 70.
    Humpe A, Riggert J, Meineke I et al. (2000) A cell-kinetic model of CD34+ cell mobilization and harvest: Development of a predictive algorithm for the CD34+ cell yield in PBPC collections. Transfusion 40: 1363–1370PubMedCrossRefGoogle Scholar
  71. 71.
    Jacquy C, Sorée A, Lambert F et al. (2000) A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin’s lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 110: 631–637PubMedCrossRefGoogle Scholar
  72. 72.
    Juttner CA, To LB, Haylock DN et al. (1985) Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 61: 739–745PubMedCrossRefGoogle Scholar
  73. 73.
    Kawachi Y, Watanabe A, Uchida T et al. (1996) Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colonystimulating factor. Br J Haematol 94: 413–416PubMedCrossRefGoogle Scholar
  74. 74.
    Kessinger A, Armitage JO, Landmark JD et al. (1986) Reconstitution of human hematopoietic function with autologous cryopre- served circulating stem cells. Exp Hematol 14: 192–196PubMedGoogle Scholar
  75. 75.
    Ketterer N, Salles G, Moullet I et al. (1998) Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 103: 235–242PubMedCrossRefGoogle Scholar
  76. 76.
    Kiss JE, Rybka WB, Winkelstein A et al. (1997) Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19: 303–310PubMedCrossRefGoogle Scholar
  77. 77.
    Körbling M, Dörken B, Ho AD et al. (1986) Autologous transplantation of blood derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt’s lymphoma. Blood 67: 529–532PubMedGoogle Scholar
  78. 78.
    Körbling M, Fliedner TM, Pflieger H (1980) Collection of large quantities of granulocyte/macrophage progenitor cells (CFUS) in man by continuous flow leukapheresis. Scand J Haematol 24: 22–28PubMedCrossRefGoogle Scholar
  79. 79.
    Körbling M, Przepiorka D, Huh YO et al. (1995) Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 85: 1659–1665PubMedGoogle Scholar
  80. 80.
    Körbling M, Ross WM, Pflieger H et al. (1977) Procurement of human blood stem cells by continuous-flow centrifugation — further comment. Blood 50: 753–754PubMedGoogle Scholar
  81. 81.
    Kröger N, Zander AR (2002) Dose and schedule effect of G-CSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma 43: 1391–1394PubMedCrossRefGoogle Scholar
  82. 82.
    Lane TA, Law P, Maruyama M et al. (1995) Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 85: 275–282PubMedGoogle Scholar
  83. 83.
    Lemoli RM, Fogli M, Fortuna A et al. (1993) Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD33-DR- cells and synergizes with stem cell factor, interleukin- 3, and granulocyte-macrophage colony-stimulating factor. Exp Hematol 21: 1668–1672PubMedGoogle Scholar
  84. 84.
    Lemoli RM, Fortuna A, Motta MR et al. (1996) Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 87: 1625–1634PubMedGoogle Scholar
  85. 85.
    Lie AKW, Hui CH, Rawling T (1998) Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant 22: 853–857PubMedCrossRefGoogle Scholar
  86. 86.
    Malachowski ME, Comenzo RL, Hillyer CD et al. (1992) Large volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 32: 732–735PubMedCrossRefGoogle Scholar
  87. 87.
    Martinez C, Urbano-Ispizua A, Rozman C et al. (1996) Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol 72: 269–272PubMedCrossRefGoogle Scholar
  88. 88.
    Mauch P, Lamont C, Neben TY et al. (1995) Hematopoietic stem cells in the blood after stem cell factor and interleukin-11 administration: evidence for different mechanisms of mobilization. Blood 86: 4674–4680PubMedGoogle Scholar
  89. 89.
    Maximow A (1909) Der Lymphozyt als gemeinsame Stammzelle der verschiedenen Blutelemente in der embryonalen Entwicklung und im postfetalen Leben der Säugetiere. Folia Haematol 8: 125–141Google Scholar
  90. 90.
    Moog R (2001) Adverse events in peripheral progenitor cell collection: a 7-year experience. J Hematother Stem Cell Res 10: 675–680PubMedCrossRefGoogle Scholar
  91. 91.
    Moog R (2002) Harvesting of CD34 antigen-expressing cells with a new programme for the collection of mononuclear cells with use of the Amicus (Baxter) blood cell separator. Transfus Med 12: 367–372PubMedCrossRefGoogle Scholar
  92. 92.
    Müller SM, Schulz AS, Reiss UM et al. (1999) Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Bone Marrow Transplant 24: 575–581PubMedCrossRefGoogle Scholar
  93. 93.
    Mutis T, Goulmy E (2002) Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin Hematol 39: 23–31PubMedCrossRefGoogle Scholar
  94. 94.
    Noga SJ, Oroszlan M, Zhang YL et al. (2002) Single dose Pegfil- grastim successfully mobilizes optimal numbers of autologous CD34+ cells for peripheral blood stem cell collection (abstract). Blood 100: 21Google Scholar
  95. 95.
    Nussbaumer W, Schönitzer D, Trieb T et al. (1996) Peripheral blood stem cell (PBSC) collection in extremely low-weight infants. Bone Marrow Transplant 18: 15–17PubMedGoogle Scholar
  96. 96.
    Olivieri A, Offidani M, Montanari M et al. (1998) Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single centre experience. Haematologica 83: 329–337PubMedGoogle Scholar
  97. 97.
    Ordemann R, Hölig K, Wagner K et al. (1998) Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors. Bone Marrow Transplant 21 (Suppl 3): S25-S28PubMedGoogle Scholar
  98. 98.
    Ottinger HD, Beelen DW, Scheulen B et al. (1996) Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 88: 2775–2779PubMedGoogle Scholar
  99. 99.
    Ottinger HD, Müller CR, Goldmann SF et al. (2001) Second german consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells. Ann Hematol 12: 706–714Google Scholar
  100. 100.
    Ottinger HD, Müller CR, Schmitz N et al. (2000) Transplant activities in Germany in 1998 — a survey facilitated by the national registry for hemopoietic stem cell transplantation. Ann Hematol 8: 437–443CrossRefGoogle Scholar
  101. 101.
    Pecora AI, Preti RA, Gleim GW et al. (1998) CD34+ CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem cell recipients. J Clin Oncol 16: 2093–2104PubMedGoogle Scholar
  102. 102.
    Porter DL, Antin JH (1999) The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 50: 369–386PubMedCrossRefGoogle Scholar
  103. 103.
    Prange-Krex G, Platzbecker U, Hölig K et al. (2000) Spleen enlargement after granulocyte colony-stimulating factor (G-CSF) mobilisation of peripheral blood stem cells (PBSC) in healthy donors (abstract). Bone Marrow Transplant 25 (Suppl 1): S253Google Scholar
  104. 104.
    Pratt G, Rawstron AC, English AE et al. (2001) Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve. Br J Haematol 114: 937–943PubMedCrossRefGoogle Scholar
  105. 105.
    Reiffers J, Bernard PH, David B et al. (1986) Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 14: 312–315PubMedGoogle Scholar
  106. 106.
    Reiffers J, Labopin M, Sanz M. et al. (2000) Autologous blood cell vs. marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplant 25: 1115–1119PubMedCrossRefGoogle Scholar
  107. 107.
    Relling MV, Boyett JM, Blanco JG et al. (2003) Granulocyte-colony stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101: 3862–3867PubMedCrossRefGoogle Scholar
  108. 108.
    Richman CM, Weiner RS, Yankee RA (1976) Increase in circulating stem cells following chemotherapy in man. Blood 47: 1031–1034PubMedGoogle Scholar
  109. 109.
    Roberts AW, DeLuca E, Begley CG et al. (1995) Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 13: 512–516PubMedCrossRefGoogle Scholar
  110. 110.
    Ruiz Arguelles GJ, Ruiz Arguelles A, Perez Romano B et al. (1995) Filgrastim mobilized peripheral blood stem cells can be stored at 4°C and used in autografts to rescue high-dose chemotherapy. Am J Hematol 48: 100–103CrossRefGoogle Scholar
  111. 111.
    Saunders G (2001) G-CSFs in daily pharmaceutical practice. Aten Farm 3: 266–270Google Scholar
  112. 112.
    Scheid C, Reiser M, Draube A et al. (2000) Mobilization with eto- poside and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF. J Hematother Stem Cell Res 9: 411–413PubMedCrossRefGoogle Scholar
  113. 113.
    Schmitz N, Bacigalupo A, Hasenclever D et al. (1998) Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21: 995–1003PubMedCrossRefGoogle Scholar
  114. 114.
    Schmitz N, Dreger P, Suttorp M et al. (1995) Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85: 1666–1672PubMedGoogle Scholar
  115. 115.
    Schmitz N, Gratwohl A, Goldman JM for Accreditation Sub-Committee of the EBMT (1996) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Bone Marrow Transplant 17: 471–477PubMedGoogle Scholar
  116. 116.
    Schmitz N, Linch DC, Dreger P et al. (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 347: 353–357PubMedCrossRefGoogle Scholar
  117. 117.
    Schreiner T, Maccari B, Erne E et al. (1996) Highly effective CD34 positive selection of G-CSF mobilized allogeneic peripheral blood progenitor cells. Blood 88: 1517–1518PubMedGoogle Scholar
  118. 118.
    Schreiner T, Wiesneth M, Krug E et al. (1998) Collection of allogeneic peripheral blood progenitor cells by two protocols on an apheresis system. Transfusion 38: 1051–1055PubMedCrossRefGoogle Scholar
  119. 119.
    Schulman, KA, Birch R, Zhen B et al. (1999) Effect of CD34+ cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 17: 1227–1233PubMedGoogle Scholar
  120. 120.
    Siena S, Di Nicola M, Danova M et al. (1996) Intergroup standardization of absolute CD34+ cell count assay for blood cell transplants for cancer therapy (abstract). In: Proceedings of the Fourth International Symposium on Blood Cell Transplantation: 6. 4Google Scholar
  121. 121.
    Smith TJ, Hillner BE, Schmitz N et al. (1997) Economic analysis of a randomized clinical trial to compare filgrastim-mobilised peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin’s and non-Hodgkin’s lymphoma. J Clin Oncol 15: 5–10PubMedGoogle Scholar
  122. 122.
    Socinski MA, Cannistra SA, Elias A et al. (1988) Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1: 1194–1198PubMedCrossRefGoogle Scholar
  123. 123.
    Stadmauer EA, Schneider CJ, Silberstein LE (1995) Peripheral blood progenitor cell generation and harvesting. Semin Oncol 22: 291–300Google Scholar
  124. 124.
    Stiff P (1999) Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 23 (Suppl 2): S29-S33PubMedCrossRefGoogle Scholar
  125. 125.
    Stiff P, Gingrich R, Luger S et al. (2000) A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transplant 26: 471–481PubMedCrossRefGoogle Scholar
  126. 126.
    Stroncek DF, Clay ME, Herr G et al. (1997) Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor-mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 37: 304–308PubMedCrossRefGoogle Scholar
  127. 127.
    Stroncek DF, Clay ME, Herr G et al. (1997) The kinetics of G-CSF mobilization of CD34+ cells in healthy people. Transfus Med 7: 19–24PubMedCrossRefGoogle Scholar
  128. 128.
    Stroncek DF, Clay ME, Jaszcz W et al. (1999) Collection of two peripheral blood stem cell concentrates from healthy donors. Transfus Med 9: 37–50PubMedCrossRefGoogle Scholar
  129. 129.
    Stroncek DF, Confer DL, Leitman SF (2000) Peripheral blood progenitor cells for HPC transplants involving unrelated donors. Transfusion 40: 731–741PubMedCrossRefGoogle Scholar
  130. 130.
    Sutherland DR, Anderson L, Keeney M et al. (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 5: 213–226PubMedCrossRefGoogle Scholar
  131. 131.
    Testoni N, Lemoli RM, Martinelli G et al. (1998) Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. Bone Marrow Transplant 22: 1065–1070PubMedCrossRefGoogle Scholar
  132. 132.
    Tichelli A, Passweg J, Hoffmann T et al. (1999) Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency. Brit J Haematol 106: 152–158CrossRefGoogle Scholar
  133. 133.
    Tsuji K, Lyman SD, Sudo T et al. (1992) Enhancement of murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit), interleukin-11, and other early acting factors in culture. Blood 79: 2855–2860PubMedGoogle Scholar
  134. 134.
    Urbano-lspizua A, Schmitz N, de Witte T et al. (2002) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 29: 639–646CrossRefGoogle Scholar
  135. 135.
    Valbonesi M, Pollicardo N, Carlier P et al. (1996) PBSC collection from G-CSF primed donors. Transfus Sci 17: 619–627PubMedGoogle Scholar
  136. 136.
    Van der Wall E, Richel DJ, Holtkamp MJ et al. (1994) Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood cell transplantation: effect of graft size. Ann Oncol 5: 795–802PubMedGoogle Scholar
  137. 137.
    Waller CF, Bertz H, Wenger MK et al. (1996) Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 18: 279–283PubMedGoogle Scholar
  138. 138.
    Weaver CH, Birch R, Greco FA et al. (1998) Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 100: 338–347PubMedCrossRefGoogle Scholar
  139. 139.
    Weaver A, Chang J, Wrigley E et al. (1998) Randomized comparison of progenitor-cell mobilization using chemotherapy, stem- cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol 16: 2601–2612PubMedGoogle Scholar
  140. 140.
    Weite K, Gabrilove J, Bronchud MH et al. (1996) Filgrastim (rmet- HuG-CSF): the first 10 years. Blood 88: 1907–1929Google Scholar
  141. 141.
    Wiesneth M, Kubanek B (1996) Richtlinien und Qualitätssicherung für die Herstellung von autologen und allogenen Blutstammzellpräparaten. J Lab Med 20: 397–400Google Scholar
  142. 142.
    Wiesneth M, Schreiner T, Friedrich W et al. (1996) Combined CD34-positive plus CD2-negative selection for effective T-cell depletion as GvHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation. Transfus Sci 17: 629–635PubMedGoogle Scholar
  143. 143.
    Wiesneth M, Schreiner T, Friedrich W et al. (1998) Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation. Bone Marrow Transplant 21 (Suppl 3): S21-S24PubMedGoogle Scholar
  144. 144.
    Wiesneth M, Schreiner T, Sandherr M et al. (1997) Haematopoietic reconstitution after autologous transplantation of CD34+-selected versus non-selected peripheral blood progenitor cells. Beitr Infusionsther Transfusionsmed 34: 133–138PubMedGoogle Scholar
  145. 145.
    Wu MH, Smith SL, Danet GH et al. (2001) Optimization of culture conditions to enhance transfection of human CD34+ cells by electroporation. Bone Marrow Transplant 27: 1201–1209PubMedCrossRefGoogle Scholar
  146. 146.
    Zeller W, Gutensohn K, Stockschläder M et al. (1996) Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin’s disease, non-Hodgkin’s lymphoma, and cancer of the testis. Bone Marrow Transplant 17: 709–713PubMedGoogle Scholar
  147. 147.
    Accreditation Manual for Blood and Marrow Progenitor Cell Processing, Collection and Transplantation. Joint Accreditation Committee of ISHAGE-Europe and EBMT (JACIE) (1999)Google Scholar
  148. 148.
    Betriebsverordnung für pharmazeutische Unternehmer (Pharm-Betr. V) BGBl. I 1994: 2071 ffGoogle Scholar
  149. 149.
    Empfehlungen zur Blutstammzellapherese der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI) (1998). Infusionsther Transfusionsmed 25: 325–335Google Scholar
  150. 150.
    Ergänzung für die »Empfehlungen zur Blutstammzellapherese« der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI) (2002). Infus Ther Transfus Med 29: 38–39Google Scholar
  151. 151.
    Manufacture and quality control of human somatic cell therapy medicinal products. The European Agency for the Evaluation of Medicinal Products — Evaluation of Medicine for Human Use (2001)Google Scholar
  152. 152.
    Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz — AMG) Neufassung vom 11. 12. 1998 BGBl. I 1998: 3586Google Scholar
  153. 153.
    Gesetz über Medizinprodukte (Medizinproduktegesetz — MPG) vom 02. 08. 1994, BGBl. I: 1963 ff, mit Änderung vom 06. 08. 1998 BGBl. I 1998: 2005 ffGoogle Scholar
  154. 154.
    Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz — TFG) vom 01. 07. 1998. BGBl. I 1998: 1752ffGoogle Scholar
  155. 155.
    Guidelines for the collection, processing and storage of human bone marrow and peripheral stem cells for transplantation. Prepared by the BCSH Blood Transfusion Task Force. Transfus Med 1994: 4: 165–172CrossRefGoogle Scholar
  156. 156.
    Richtlinie der Kommission zur Festlegung der Grundsätze und Leitlinien der Guten Herstellungspraxis (GMP) für zur Anwendung beim Menschen bestimmte Arzneimittel (91/356/EWG) vom 13. 06. 91Google Scholar
  157. 157.
    Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie), aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer und vom Paul-Ehrlich-Institut (2000)Google Scholar
  158. 158.
    Richtlinien zur Transplantation peripherer Blutstammzellen. Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer unter Mitwirkung des Paul-Ehrlich-Institutes. Deutsches Ärzteblatt 1997: 94: A1584–1591Google Scholar
  159. 159.
    Lippert H-D, Flegel WA (2002) Kommentar zum Transfusionsgesetz (TFG) und den Hämotherapie-Richtlinien. Springer, Berlin Heidelberg New York TokioCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • M. Wiesneth

There are no affiliations available

Personalised recommendations